This page shows the latest Therakos news and features for those working in and with pharma, biotech and healthcare.
bought Cadence Pharma for $1.3bn, Questcor for $6.5bn, immunotherapy outfit Therakos for $1.3bn and nuclear imaging specialist IBA Molecular for £690m in the last three years.
To that end the company signed two deals in 2015, namely a $1.3bn deal to buy immune cell therapy specialist Therakos and the $2.3bn purchase of hospital treatments company
Therakos specialises in autologous immune cell therapy delivered through extracorporeal photopheresis (ECP) - essentially developing treatment platforms that harness the power of patients' immune systems to fight disease. ... Therakos therapeutic
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
30600. Therakos. Mallinckrodt. Approved cell therapy platform for the palliative treatment of cutaneous T‐cell lymphoma [CTCL].
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
No results were found
We are Mtech Access, a global market access and health economics and outcomes research (HEOR) consultancy supporting top Pharmaceutical companies,...